Skip to main content

Mouse ICAM-1/CD54 Antibody

R&D Systems, part of Bio-Techne | Catalog # AF796

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AF796
AF796-SP

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Mouse

Cited:

Human, Mouse, Hamster, Transgenic Mouse

Applications

Validated:

Adhesion Blockade, Immunohistochemistry, Western Blot

Cited:

Immunocytochemistry, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Neutralization, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse ICAM-1/CD54
Gln28-Asn485
Accession # Q3U8M7

Specificity

Detects mouse ICAM-1 in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant rat ICAM-1 is observed, approximately 5% cross-reactivity with recombinant human (rh) ICAM-1 and rhICAM-3 is observed, and less than 1% cross-reactivity with recombinant mouse ICAM-2 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Mouse ICAM-1/CD54 Antibody

ICAM-1/CD54 antibody in Mouse Testis by Immunohistochemistry (IHC-Fr).

ICAM‑1/CD54 in Mouse Testis.

ICAM-1/CD54 was detected in perfusion fixed frozen sections of mouse testis using Goat Anti-Mouse ICAM-1/CD54 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF796) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to plasma membrane in Leydig cells. View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.
Detection of Mouse ICAM-1/CD54 by Western Blot

Detection of Mouse ICAM-1/CD54 by Western Blot

Increased stress kinase signaling and JNK pathway-dependent cytokine and chemokine production by primary keratinocytes lacking BRAF and RAF1.(A) Reduced ERK phosphorylation and increased JNK/p38 activation in primary delta/ deltaep2 keratinocytes stimulated with EGF and/or TNF alpha and IL1 beta for 15 min. (B) Increased cytokine and chemokine production in primary delta/ deltaep2 keratinocytes treated with EGF, TNF alpha and IL1 beta for 24 hr. Cytokine and chemokine production was determined by multiplex analysis, except for TSLP which was quantified by ELISA. Data represent mean ± SEM of 3–5 biological replicates. (C–D) Cells were pretreated with D-JNKI1 inhibitors prior to stimulation with EGF, TNF alpha and IL1 beta for 15 min (C) or 24 hr (D). Data represent the mean ± SEM of technical replicates (n = 3). (E–F) Effect of shRNA-mediated Mlk3 silencing on ERK and JNK phosphorylation and ICAM1 expression (E; stimulation with EGF, TNF alpha and IL1 beta for 15 min) and on the expression of Ccl2 and Tslp mRNA (F; stimulation with EGF, TNF alpha and IL1 beta for 24 hr) by F/F2 and delta/ deltaep2 keratinocytes. shRen, shRNA targeting Renilla, used as a control; sh1 and sh2, targeting Mlk3, binding sites nucleotide 2266–2285 and 2383–2402, respectively. The shRNAs were encoded by lentiviral vectors coexpressing GFP. GFP immunoblots are shown to confirm similar levels of infection in all samples. Data represent mean ± SEM of 4 biological replicates. Each keratinocyte culture represents a pool of three mice. Immunoblots are representative of three independent experiments. p1 = 0.041, p2 = 0.040, p3 = 1.89E-4, p4 = 0.018, p5 = 0.046, p6 = 0.020, p7 = 0.008, p8 = 0.016, p9 = 0.001, p10 = 0.018, p11 = 3.23E-4, p12 = 1.47E-4, p13 = 0.007, p14 = 0.03, p15 = 0.035, p16 = 0.023 and p17 = 0.046.DOI:https://dx.doi.org/10.7554/eLife.14012.018Compound knockdown (KD2) of BRAF and RAF1 induce the expression of inflammation markers by HaCat cells in a MLK3/JNK-dependent manner.(A) Reduced ERK and increased JNK/p38 activation in BRAF and RAF1 knockdown (KD2) HaCat cells stimulated with EGF, TNF alpha and IL1 beta for 15 min. (B) D-JNKI1 reduces ICAM1 and CCL2 (n = 4) expression in KD2 cells treated with TNF alpha. (C) MEKi induces ICAM1 and CCL2 (n = 3) expression in RAF1KD cells treated with TNF alpha. In (B–C), ICAM1 expression was measured after a 3 hr, CCL2 expression after a 24 hr treatment with TNF alpha. (D) Effect of MLK3 silencing on ERK and JNK phosphorylation in WT and KD2 cells stimulated as in (A). MLK3 was silenced using a pool of oligonucleotides targeting the following regions: 686–704; 1489–1507; 2122–2138; and 2348–2366. MLK3 KD cells stimulated as in (B–C) show a decrease in JNK activation, ICAM1 and CCL2 (n = 7) expression. Immunoblots are representative of three independent experiments. qPCR data represent mean ± SEM of three independent experiments run in duplicates (p1 = 4.62E-4, p2 = 0.013, p3 = 0.050, p4 = 8.60E-8, p5 = 0.050, p6 = 0.001, p7 = 0.001 and p8 = 0.012).DOI:https://dx.doi.org/10.7554/eLife.14012.019 Image collected and cropped by CiteAb from the following publication (https://elifesciences.org/articles/14012), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Mouse ICAM-1/CD54 by Western Blot

Detection of Mouse ICAM-1/CD54 by Western Blot

Increased stress kinase signaling and JNK pathway-dependent cytokine and chemokine production by primary keratinocytes lacking BRAF and RAF1.(A) Reduced ERK phosphorylation and increased JNK/p38 activation in primary delta/ deltaep2 keratinocytes stimulated with EGF and/or TNF alpha and IL1 beta for 15 min. (B) Increased cytokine and chemokine production in primary delta/ deltaep2 keratinocytes treated with EGF, TNF alpha and IL1 beta for 24 hr. Cytokine and chemokine production was determined by multiplex analysis, except for TSLP which was quantified by ELISA. Data represent mean ± SEM of 3–5 biological replicates. (C–D) Cells were pretreated with D-JNKI1 inhibitors prior to stimulation with EGF, TNF alpha and IL1 beta for 15 min (C) or 24 hr (D). Data represent the mean ± SEM of technical replicates (n = 3). (E–F) Effect of shRNA-mediated Mlk3 silencing on ERK and JNK phosphorylation and ICAM1 expression (E; stimulation with EGF, TNF alpha and IL1 beta for 15 min) and on the expression of Ccl2 and Tslp mRNA (F; stimulation with EGF, TNF alpha and IL1 beta for 24 hr) by F/F2 and delta/ deltaep2 keratinocytes. shRen, shRNA targeting Renilla, used as a control; sh1 and sh2, targeting Mlk3, binding sites nucleotide 2266–2285 and 2383–2402, respectively. The shRNAs were encoded by lentiviral vectors coexpressing GFP. GFP immunoblots are shown to confirm similar levels of infection in all samples. Data represent mean ± SEM of 4 biological replicates. Each keratinocyte culture represents a pool of three mice. Immunoblots are representative of three independent experiments. p1 = 0.041, p2 = 0.040, p3 = 1.89E-4, p4 = 0.018, p5 = 0.046, p6 = 0.020, p7 = 0.008, p8 = 0.016, p9 = 0.001, p10 = 0.018, p11 = 3.23E-4, p12 = 1.47E-4, p13 = 0.007, p14 = 0.03, p15 = 0.035, p16 = 0.023 and p17 = 0.046.DOI:https://dx.doi.org/10.7554/eLife.14012.018Compound knockdown (KD2) of BRAF and RAF1 induce the expression of inflammation markers by HaCat cells in a MLK3/JNK-dependent manner.(A) Reduced ERK and increased JNK/p38 activation in BRAF and RAF1 knockdown (KD2) HaCat cells stimulated with EGF, TNF alpha and IL1 beta for 15 min. (B) D-JNKI1 reduces ICAM1 and CCL2 (n = 4) expression in KD2 cells treated with TNF alpha. (C) MEKi induces ICAM1 and CCL2 (n = 3) expression in RAF1KD cells treated with TNF alpha. In (B–C), ICAM1 expression was measured after a 3 hr, CCL2 expression after a 24 hr treatment with TNF alpha. (D) Effect of MLK3 silencing on ERK and JNK phosphorylation in WT and KD2 cells stimulated as in (A). MLK3 was silenced using a pool of oligonucleotides targeting the following regions: 686–704; 1489–1507; 2122–2138; and 2348–2366. MLK3 KD cells stimulated as in (B–C) show a decrease in JNK activation, ICAM1 and CCL2 (n = 7) expression. Immunoblots are representative of three independent experiments. qPCR data represent mean ± SEM of three independent experiments run in duplicates (p1 = 4.62E-4, p2 = 0.013, p3 = 0.050, p4 = 8.60E-8, p5 = 0.050, p6 = 0.001, p7 = 0.001 and p8 = 0.012).DOI:https://dx.doi.org/10.7554/eLife.14012.019 Image collected and cropped by CiteAb from the following publication (https://elifesciences.org/articles/14012), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Mouse ICAM-1/CD54 Antibody

Application
Recommended Usage

Adhesion Blockade

The adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells (5 x 104 cells/well) to immobilized Recombinant Mouse ICAM-1 Fc Chimera (Catalog # 796-IC, 5 µg/mL, 100 µL/well) was maximally inhibited (80-100%) by 5 µg/mL of the antibody.

Immunohistochemistry

5-15 µg/mL
Sample:  Perfusion fixed frozen sections of mouse testis

Western Blot

0.1 µg/mL
Sample: Recombinant Mouse ICAM-1/CD54 Fc Chimera (Catalog # 796-IC)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 8 reviews rated 4.5 using AF796 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: ICAM-1/CD54

Intercellular Adhesion Molecule-1 (ICAM-1, CD54) binds the leukocyte integrins LFA-1 and Mac-1. ICAM-1 expression is weak on leukocytes, epithelial and resting endothelial cells, as well as some other cell types, but expression can be stimulated by IFN-gamma, TNF-alpha, IL-1 beta, and LPS. Mouse and human ICAM-1 share approximately 54% amino acid identity.

Soluble ICAM-1 is found in a biologically active form in serum, probably as a result of proteolytic cleavage from the cell surface, and is elevated in patients with various inflammatory syndromes such as septic shock, leukocyte adhesion deficiency syndrome (LAD), cancer, and transplantation.

References

  1. Pigott, R. and C. Power (1993) in The Adhesion Molecule Facts Book. Academic Press, p. 74.
  2. Siu, G. et al. (1989) J. Immunol. 143:3813.
  3. Ballantyne, C.M. et al. (1989) Nuc. Acid. Res. 17:5853.

Long Name

Intercellular Adhesion Molecule 1

Alternate Names

CD54, ICAM1

Entrez Gene IDs

3383 (Human); 15894 (Mouse); 25464 (Rat)

Gene Symbol

ICAM1

UniProt

Additional ICAM-1/CD54 Products

Product Documents for Mouse ICAM-1/CD54 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Mouse ICAM-1/CD54 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...